What is Frontier Biotechnologies Inc.'s (688221.SS) StockRank?

MoatMap's StockRank for Frontier Biotechnologies Inc. (688221.SS) is 21/100, with a Sell signal. This is a composite score combining Quality (50), Value (14), and Momentum (47) factor ranks across MoatMap's 20,000+ stock universe.

Does Frontier Biotechnologies Inc. have an economic moat?

Frontier Biotechnologies Inc. (688221.SS) has a Quality factor score of 50/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Frontier Biotechnologies Inc. a buy, hold, or sell?

MoatMap's current signal for Frontier Biotechnologies Inc. (688221.SS) is Sell, based on a StockRank of 21/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Frontier Biotechnologies Inc. in?

Frontier Biotechnologies Inc. (688221.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688221.SS

SELLREMOVE

Frontier Biotechnologies Inc. · Healthcare · China · $1.1B · Avg Vol: $38M/d

StockRank

P/E (TTM)

1786.0x

ROE

0.3%

D/E

0.4x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

An early-stage biotech firm with high cash burn and binary clinical trial risks, failing our requirement for established, high-ROIC compounders.

COMPANY DESCRIPTION

Frontier Biotechnologies is a commercial-stage biopharmaceutical company focused on the discovery and development of innovative anti-infective therapies, particularly for HIV. Its flagship product, Aikening, is China's first domestically developed long-acting HIV fusion inhibitor, establishing a strong first-mover advantage and clinical moat. The company operates as a highly specialized niche leader with a robust pipeline targeting viral infections and inflammatory diseases.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	13M	17M	19M	18M	13.3%
EPS	-0.14	-0.13	-0.08	-0.11	—
Shares	375M	375M	375M	375M	0.0%
Debt	43M	57M	63M	60M	12.3%
Equity	247M	198M	169M	130M	-19.3%
Op CF	-43M	-39M	-25M	-33M	—
Inv CF	-17M	26M	-28M	26M	—
Fin CF	24M	10M	13M	-4M	—

PRICE (1M)-19.5%

SMA 50SMA 200

$2.64

RSI (14)

17.0

52W High

$4.43

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-22.2%27.1

ROE

0.3%45.4

GP/Assets

19.6%45.7

Op. Margin

76.0%99.5

FCF/Assets

-8.1%30.6

Piotroski

—83.4

Int. Cover

-28.4x17.2

D/E Ratio

0.43x35.4

Current Ratio

3.54x59.2

Value

P/E (TTM)

1786.0x1.3

EV/EBITDA

223.7x1.2

P/FCF

—N/A

P/B

6.0x19.6

P/S

17.1x18.7

Div Yield

—N/A

Momentum

52W High %

60%39.7

RS 6M

-16%61.6

SMA 50/200

1.06x73.9

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.1B

P/E (Forward)

-23.8x

Gross Margin

78.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688221.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
688221.SS	Frontier Biotechnologies Inc.(you)	$1.1B	21	SELL
600812.SS	North China Pharmaceutical Company.Ltd	$1.2B	21	SELL
600129.SS	Chongqing Taiji Industry(Group) Co.,Ltd	$1.2B	23	SELL
688276.SS	Changchun BCHT Biotechnology Co.	$975M	21	SELL
002099.SZ	Zhejiang Hisoar Pharmaceutical Co., Ltd.	$1.3B	21	SELL
600422.SS	KPC Pharmaceuticals,Inc.	$999M	24	SELL
002940.SZ	Zhejiang AngLiKang Pharmaceutical CO.,LTD.	$1.0B	25	SELL
300363.SZ	Porton Pharma Solutions Ltd.	$1.2B	26	SELL
300702.SZ	Zhejiang Tianyu Pharmaceutical Co., Ltd.	$989M	26	SELL
603567.SS	Heilongjiang ZBD Pharmaceutical Co., Ltd.	$994M	26	SELL

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.0%

Frontier Biotechnologies Inc. (688221.SS) — Stock Score Summary

Frontier Biotechnologies Inc. (688221.SS) has a MoatMap StockRank of 21/100 based on Quality (50/100), Value (14/100), and Momentum (47/100) factor scores. The current signal is SELL. An early-stage biotech firm with high cash burn and binary clinical trial risks, failing our requirement for established, high-ROIC compounders.

Key Financial Metrics

Price	$2.64
Market Cap	$1.1B
P/E (TTM)	1786.00
P/E (Forward)	-23.81
Price/Book	6.04
Return on Equity	0.3%
Return on Invested Capital	-22.2%
Debt/Equity	42.55
Gross Margin	78.6%
Operating Margin	76.0%
Revenue Growth	948.9%
Free Cash Flow	$-3M

Frontier Biotechnologies Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Frontier Biotechnologies Inc.’s (688221.SS) StockRank?: MoatMap’s StockRank for Frontier Biotechnologies Inc. (688221.SS) is 21/100, with a Sell signal. It is a composite of Quality (50), Value (14), and Momentum (47) factor ranks across MoatMap’s 20,000+ stock universe.
Does Frontier Biotechnologies Inc. have an economic moat?: Frontier Biotechnologies Inc. (688221.SS) has a Quality factor score of 50/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Frontier Biotechnologies Inc. a buy, hold, or sell?: MoatMap’s current signal for Frontier Biotechnologies Inc. (688221.SS) is Sell, based on a StockRank of 21/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Frontier Biotechnologies Inc. in?: Frontier Biotechnologies Inc. (688221.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).